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Abstract
Genetically modified animals are a widely used tool in biomedical research, since it allows 
modeling diseases, studying their pathological conditions and identifying and validat-
ing new drugs. One of the most common diseases studied in recent years is metabolic 
disorders resulting from abnormalities in enzyme systems involved in the intermediary 
metabolism of living organisms with a heavy impact on society. To understand the physi-
ological mechanisms underlying these disorders, animal models, currently the transgenic 
type, have been employed. It is important to emphasize that there are various metabolic 
disorders that are not only congenital but can be acquired or a coexistence of both types. The 
aim of this chapter, therefore, is to describe the most commonly used rodent models focus-
ing mainly on global emerging pathologies, obesity, diabetes and metabolic syndrome.
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1. Introduction
The use of experimental animals involved in metabolic pathologies goes back a few hundred 
years. Various mammals such as dogs, rabbits, pigs, primates and rats were frequently used 
by researchers to understand the physiological mechanism of diseases from the pancreotomy 
to isolation and purification of insulin in the 1920s to the use of toxic compounds to cause dis-
ease and the current use of genetically modified animals [1]. The advantages of using rodents 
for experimentation are several since it can be improved on besides the reproducibility and 
reliability of the study results. As expected, animal models for metabolic diseases are as com-
plex and heterogeneous as the diseases themselves, since each one of them has specific modi-
fications incomparable with others. Moreover, inbred lines continue, while new endogenous 
lines are used in many fields of research [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Most metabolic diseases in humans are a consequence of the rupture of cellular processes. 
However, the relationships between genetic defects, underlying molecular interaction networks 
and phenotypic expression, are little known [3]. Congenital metabolic diseases are disorders 
produced by a variation in the coding sequence of the DNA resulting in deficiencies or absence 
of a protein, generally an enzyme, producing metabolic blockages, whereas acquired metabolic 
diseases are due to diseases of endocrine organs or failure of metabolically active organs [4] 
(Figure 1). In this regard, the chapter focused mainly on both genotypic and phenotypic char-
acteristics of animal models employed in the investigation of emerging metabolic diseases.
2. Mouse models
Current research has seen the increased use of animal models in exploring mechanisms and 
pathophysiological processes involved in metabolic diseases (Table 1) both in congenital and 
in acquired disease conditions, more importantly in the design and development of therapeu-
tics and drugs for treatment.
Figure 1. Congenital and metabolic disorders.
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Disease Model Features References
Congenital
Fabry disease GLAko mouse Mouse with a complete lack of α-galactosidase A 
activity. Appear clinically normal, with normal 
blood and urine analyses and a normal adult 
lifespan
[5]
Phenylketonuria PKU mouse A significantly decrease in level of Phe in the 
plasma
[6]
Prader-Willi syndrome Snrpntm2Cbr mouse The mouse exhibits postnatal lethality [7]
Galactosemia GalT KO mouse Accumulated some galactose and its metabolites 
upon galactose challenge but was seemingly fertile 
and symptom free
[8]
Tay-Sachs’s disease Tay-Sachs (Hexa−/−) 
mouse
In females there are severe progressive hind-limb 
weaknesses with impaired motor coordination, 
balance and mild ataxia
[9]
Porphyria Uros(mut248) mouse Production of red urine and shows erythrodontia. 
Bones are abnormally fragile
[10]
Pompe disease GAA−/− mouse A progressive accumulation of lysosomal glycogen 
in heart and skeletal muscle and diaphragm
[11]
Niemann-Pick disease ASM (−/−) mouse A severe, neurodegenerative course and death that 




MPS VI mouse A skeletal and chondral dysplasia [13]
Hunter syndrome IDS-deficient mouse A progressive accumulation of 
glycosaminoglycans (GAG) in many organs and 
excessive excretion of these compounds in their 
urine.Neuropathological defects
[14]
Lesh-Nyhan syndrome HPRT-deficient 
mouse
Changes in brain dopamine function [15]
Hurler syndrome MPS I-H KO mouse Mice showed no detectable α-l-iduronidase 
activity
[16]
Homocystinuria “human only” (HO) 
mouse
Severe elevations in both plasma and tissue levels 
of Hcy, methionine, S-adenosylmethionine and 
S-adenosylhomocysteine and a concomitant 
decrease in plasma and hepatic levels of cysteine
[17]
Hartnup HPH2 mouse A deficient amino acid transport [18]
Acquired
Dyslipidemia LDLR−/− mouse A severe hyperlipidemia and extensive 
atherosclerosis
[19]
apoE−/− mouse A more severe hyperlipidemia characterized by 
elevations in VLDL and reductions in HDL, which 
lead to spontaneous atherosclerosis
[20]
Hyperuricemia Induced by 
hypoxanthine
An increase in urinary uric acid [21]
Table 1. Summary of model rodents of some congenital or acquired metabolic diseases.
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2.1. Type 2 diabetes models
Type 2 diabetes (T2D) is a metabolic disorder that is caused by insufficient insulin secretion 
and/or insulin resistance in peripheral tissues and liver [22]. To help develop new diabetic ther-
apies, it is important to highlight the complex mechanisms of diabetes mellitus. Animal models 
of T2D are as complex and heterogeneous as the syndrome itself as experienced in humans.
2.1.1. db/db mice
These diabetic mutant mice are modifications of the C57BL strain [23, 24]. The mutation in 
the leptin OB-R receptor was identified in 1996, and this model has been widely used in the 
evaluation of antiobesity and antidiabetic compounds and therapies due to its manifestation 
of hyperphagia and morbid obesity, reproductive failure and severe insulin resistance [25].
2.1.2. BKS db mice
The C57BLKS/J (BKS) consanguine mouse strain is a widely used animal model of T2D. A reces-
sive mutation that occurs spontaneously in the BKS strain produces early-onset diabetes and 
obesity with moderate initial hyperinsulinemia followed by insulinopenia since pancreatic 
islets undergo atropia due to degeneration of β cells [25]. Moreover, they show polyphagia and 
obesity and a marked increase in weight and blood glucose after 3–4 weeks of their birth [26, 27].
2.1.3. KKAy mice
The KKAy mouse, due to its genetic mutation, is the spontaneous animal model of hyper-
glycemia and hyperlipidemia and its symptoms are similar to T2D [28]. The mutation Ay 
often becomes obese and infertile within months after birth, and the observed increase in the 
adipose tissue is due to hypertrophy of fat cells; however, obesity results from a reduction 
in hypothalamic norepinephrine and dopamine [29]. In this strain of mice, diabetic charac-
teristics such as obesity, hyperinsulinemia and hyperglycemia are observed in early ages, 
between the 6th and 8th week, and then return to normal at approximately 40 weeks of age. 
Degranulation, glycogen deposition and hypertrophy of β cells are observed in these animals 
at 5–10 weeks of age, suggesting that insulin synthesis and release are increased with hyperin-
sulinemia. Renal lesions such as diffuse glomerulosclerosis, nodular changes and thickening 
of the peripheral glomerular basement membrane are also observed [29].
2.1.4. BTBR obese mice
BTBR obese mice have more fat mass than most strains of inbred mice [30]. The BTBR model 
naturally suffers from hyperinsulinemia when compared to other insulin-resistant mice, but 
when the ob/ob mutation is placed on a BTBR background, the mice are initially insulin resis-
tant with elevated insulin levels, hypertrophy of pancreatic islets and marked hyperglycemia 
at 6 weeks of age [31]. An important feature of this model is the degree to which it reproduces 
the essential structural and functional characteristics of the human diabetic glomerular lesion 
with glomerular hypertrophy, marked expansion of the mesangial matrix, mesangioisis and 
capillary thickening of the basal membrane as well as loss of podocytes [32].
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2.1.5. eNOS−/− mice
The gene-encoding eNOS or endothelial nitric oxide synthase has been considered a potential 
candidate gene for diabetic nephropathy because of nephropathic changes observed in mouse 
models of T1D and T2D, thus mimicking many aspects of human diabetic disease [33]. The 
eNOS −/− mice develop a remarkable albuminuria and pathological change characteristics 
of T2D such as mesangiolysis, microaneurysms and expansion of the increased mesangial 
matrix. It is useful to study the role of endothelial dysfunction in the development of diabetes 
and to facilitate the development of new diagnostic and therapeutic interventions [34].
2.1.6. ALR/LtJ mice
Resistant mouse (R) Leiter (LT) resistant to alloxan (AL) is closely related to the nonobese dia-
betic (NOD) strain. This model presents an unusual high quantitative expression of molecules 
associated with systemic dissipation of cell stress from free radicals. The islets of ALR are 
remarkably resistant to two different combinations of cytokines (IL-1β, TNF-α and IFN-γ) that 
destroy islets of NOD strains susceptible to alloxan [35], and this mechanism induces diabetes 
mellitus [36]. The strain derived from Swiss mice is widely used to study insulin-dependent 
diabetes mellitus in mice.
2.1.7. B6.HRS(BKS)-Cpefat/J
They are homozygous mice obtained by spontaneous fat mutation (Cpefat) on a genetic back-
ground, that is, C57BL/6J. They become remarkably obese at 14–15 weeks of age; male homo-
zygous mutant mice develop obesity at a later age than females [37]. Cpefat mice weigh less 
than wild-type controls before the weaning age. Later, homozygous mutant mice develop a 
diabetic phenotype characterized by hyperglycemia and insulin resistance [38].
2.1.8. LG/J and SM/J
The large-LG/J and small-SM/J strains are inbred mice derived from selection experiments for 
large and small body size at 60 days [39]; LG/J animals grow faster at 3–10 weeks and have 
larger tissues at tails, body and liver and higher content of body fat compared with the SM/J 
strain. SM/J animals grow faster after 10 weeks of age and have higher fasting glucose levels 
than LG/J animals. SM/J mice are more sensitive to dietary fat gain than LG/J mice for growth 
after 10 weeks. Moreover, LG/J mice are more susceptible to develop antinuclear antibodies 
and rheumatoid factor, as well as renal disease characterized by glomerulonephritis, interstitial 
nephritis and perivasculitis [40].
2.1.9. NOD/ShiLtJ-Leprdb-5J/LtJ
Nonobese diabetic (NOD) mouse is an endocrine strain developed during a breeding program 
to establish a cataract-prone subline of non-consanguineous mice [41]. They are homozygous 
co-isogenic NOD mice, which develop juvenile diabetes and T2D along with the suppression 
of post-adolescent age-dependent spontaneous T1D. At 5 weeks of age, these mice are hyper-
phagic; they eat twice the amount of food from a lean control mouse and develop hypergly-
cemia that does not require insulin therapy for long-term survival [42].
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2.2. Type 1 diabetes
After the discovery of insulin, the availability of animal models for the study of the pathogen-
esis of T1D was delayed by approximately 50 years.
2.2.1. Ins2Akita mutants
A point mutation of the insulin gene 2 in Insta mice (Akita) leads to a pancreatic apoptosis of 
β cells and hyperglycemia. Thus, these mice are commonly used to investigate T1D complica-
tions [43]. Symptoms in heterozygous mutant mice include hyperglycemia, hypoinsulinemia, 
polydipsia and polyuria beginning at about 3–4 weeks of age. Mice have progressive loss of 
β-cell function and decreased pancreatic cell density and significant hyperglycemia at 4 weeks 
of age [44]. It is a model used primarily for the study of retinal complications in T1D [45].
2.2.2. Streptozotocin-treated mice
Streptozotocin (STZ)-induced diabetes mellitus (STZ) offers a very cost-effective and expedi-
ent technique that can be used in most rodent strains, opening the field of diabetes mellitus 
research to a range of genotypic and phenotypic options that would otherwise be inacces-
sible. Since the initial report of its diabetogenic properties in 1963, STZ has been used alone 
or in combination with other chemicals or with dietary manipulations for the induction of 
either T1D or T2D through toxicity of β cells. STZ sensitivity is highly variable in rodents like 
DBA/2, C57BL/6, MRL/MP, 129/SvEv and BALB/c [46].
2.3. Obesity
The search for new alternatives for prevention and/or treatment to combat global chronic 
diseases such as obesity is based on the development of new animal models that share char-
acteristics of these human diseases [47].
2.3.1. ob/ob
A spontaneous mutation leading to the markedly obese phenotype in the ob/ob mice was 
recognized since the 1950s. C57BL/6J mice with a mutation in the obese (ob) gene are obese, 
diabetic and exhibit reduced activity, metabolism and body temperature. The obesity syn-
drome of ob/ob mice results from lack of leptin characterized by hyperphagia, reduced energy 
expenditure and hypothermia; further defects are hypercorticosteronemia, insulin resistance 
associated with hyperglycemia and hyperinsulinemia, hypothyroidism and growth hormone 
deficiency leading to a decrease in linear growth. Moreover, ob/ob mice are infertile. The 
administration of exogenous leptin normalizes all known phenotypic defects in ob/ob mice 
including obesity, symptoms of the metabolic syndrome and reproductive function [47–50].
2.3.2. C57BL/6J DIO
Diet-induced models of obesity (DIO) are often used to study polygenic causes of obesity. 
DIO animals mimic the state of common obesity in humans than most of the genetically 
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modified models and may be the best choice for testing prospective therapeutics [47]. 
Numerous mouse strains are susceptible to DIO, including C57BL/6 [51]. This mouse devel-
ops obesity, hyperinsulinemia, hyperglycemia and hypertension [52].
2.3.3. NONcNZO10/LtJ
The NONcNZO10/LtJ mouse is a polygenic model of T2D that shows moderate obesity and 
diabetes. This model of obesity-induced diabetes was produced by the combination of quanti-
tative trait loci from the New Zealand Obese (NZO/HlLt) and Nonobese Nondiabetic (NON/
LtJ) mice. Interestingly, the NONcNZO10/LtJ males do not exhibit hypercorticism, hyperphagic 
behavior and obvious thermoregulatory defect. However, they develop visceral obesity, maturity-
onset hyperglycemia, dyslipidemia, moderate liver steatosis and pancreatic islet atrophy [53, 54].
2.3.4. TALLYHO/JngJ
TALLYHO/JngJ (TH, formerly TallyHo) is a polygenic mouse that shows obesity, hyperinsu-
linemia, hyperglycemia (males) and hyperlipidemia at 26 weeks of age [55]. TallyHo mice can 
be resistant to hypothalamic leptin at 4 weeks of age due to the increased expression of orexi-
genic neuropeptides in the hypothalamus with no alteration of food intake and neuropep-
tide expression when intravenously treated with leptin [56]. Male TallyHo mice can develop 
hyperglycemia, hyperinsulinemia, hyperlipidemia, moderate obesity and enlargement of the 
islets of Langerhans. Female mice display moderate hyperinsulinemia, hyperlipidemia and 
obesity but do not manifest overt diabetes (hyperglycemia) [57].
2.3.5. B6(cg)-Tubtub/J
Mice homozygous for the tubby spontaneous mutation B6(Cg)-Tubtub/J develop obesity at 
the onset of maturity. Specifically, these mice show increased body weight at 3–4 months, 
whereas the females show this increase at 4–6 months. The increased body weight is due to 
an increased accumulation of adipose tissue. Blood glucose is normal, but plasma insulin is 
increased prior to obvious signs of obesity and may rise to 20 times normal at 6 months. The 
levels of total cholesterol, triglycerides and high-density lipoprotein cholesterol are increased 
in plasma of homozygous mutant mice; despite this, these mice do not exhibit atherosclerotic 
fatty streak blood vessel lesions. Importantly, both genders are fertile [58, 59].
2.3.6. Obesity induced by diet
Animal models of obesity that are similar to the human are very important to study the patho-
physiology of obesity. The obese mouse model induced by high-fat diet (HFD) is one of the 
most important tools for understanding the relation between high-fat diets and the patho-
physiology of development of obesity.
2.3.6.1. High-fat diet-fed mice
The high-fat diet (HFD)-fed mouse is a model of obesity, impaired glucose tolerance and 
insulin resistance [60]. The development of disease-induced dietary fat can be divided into 
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three stages: (1) an early stage in response to a high-fat diet in which mice were sensitive to 
exogenous leptin; (2) a reduced stage of food intake when mice had an increase in milk pro-
duction and still retained central leptin sensitivity; and (3) a stage of increased food intake 
and accompanied by reduced sensitivity to the central leptin [61].
2.3.6.2. High carbohydrate-fed mice
The hypercaloric diets (HCDs) induce hyperglycemia by inducing tolerance to glucose and 
increasing the levels of TAG, TNF-α and MCP-1/JEin plasma. Moreover, the HCD increases 
the MCP-1/JE levels in target organs such as the adipose tissue and liver. However, the 
HC diet also can increase TNF-α concentration in the liver [62]. It is important to men-
tion that the HFD is more effective to induce the body weight gain as compared with the 
HCD because of the large storage capacities of the adipose tissue and the low satiating 
effects of HFD as compared to the low capacities of the glycogen stores and of the de novo 
lipogenesis cost [63, 64].
2.4. Other metabolic syndromes
The metabolic syndrome (MetS) models are important to understand the pathophysiologi-
cal basis of the MetS and how this syndrome increases the risk to the development of severe 
complications. The MetS animal model most commonly used is the obese mouse strains with 
several spontaneous mutations, which have been used for decades and are very well charac-
terized. Moreover, inducing MetS with high-fat diet requires only some months, and these 
models are useful to study the effects of single genes by developing transgenic or gene knock-
outs to determine the influence of a gene on MetS [19, 65].
2.4.1. B6.129S7-Ldlrtm1Her/J
This mouse homozygous mutation has an elevated serum cholesterol level of 200–400 mg/dl 
and they attain very high levels (>2000 mg/dl) when fed with a HFD. Normal levels of serum 
cholesterol in the mouse are 80–100 mg/dl [66].
2.4.2. B6.Cg-Ay/J
The heterozygote mouse has increased the adipose tissue mass due to fat-cell hypertro-
phy and later develops insulin resistance and hyperglycemia. Heterozygote mice are also 
more susceptible to develop tumors than the normal mice, and their spleen cells cause a 
significantly lower graft versus host reaction. The level of malic enzyme in the liver is 
elevated [67].
2.4.3. NON/ShiLtJ
These mouse models are extremely useful for research works on obesity, diabetes, dyslipid-
emia and hypertension. NON/ShitLtJ (nondiabetic obese) mice contain an MHC haplotype 
resistant to diabetes and demonstrate early impaired glucose tolerance in both genders. These 
mice do not generate obesity when they are fed a diet containing 6% fat [68, 69].
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3. Rat models
3.1. Type 2 diabetes
3.1.1. Goto-Kakizaki rats
This rat strain was developed by the selective selection of Wistar rats for glucose intoler-
ance over multiple generations, resulting in a polygenic strain that spontaneously develops 
hyperglycemia with problems in β-cell function. The hyperglycemia that these rats present 
is due to an increase of gluconeogenesis. Goto-Kakizaki (GK) rats have been considered one 
of the best nonobese T2D animal models. They are thin rats but present hyperglycemia and 
increased gluconeogenesis. GK rats present valuable characteristic tools that are commonly 
and functionally present in human diabetic patients [70, 71].
3.1.2. Streptozotocin-treated rat
This experimental model is useful for studying the regeneration of β cells in which damage to 
cells is caused by the injection of STZ. In this strain, regeneration of the cells is a complication, 
which is decreased in adult rats and thus presents a chronic pathological pattern like human 
T2D, glucose intolerance and low insulin in response to glucose [72, 73].
3.1.3. Pancreatomized Sprague-Dawley rats
To create this model of rats, Sprague-Dawley rats underwent simulated pancreatectomy. One 
week later, animals develop chronic hyperglycemia that is stable for several weeks without 
significant alterations in fatty acid levels. It is a strain used for the homeostatic control of the 
mass of the β cells to produce insulin in both the normal pancreatic growth and during the 
pathogenesis of diabetes. It is a multipurpose albino model, and primarily evidence of obesity 
is induced by diet, diabetes and oncology [74, 75].
3.2. Diabetic nephropathy
A very common treatment to obtain this model of rat is the application of streptozotocin, 
creating rats with diabetic conditions that develop kidney injury, similar to human diabetic 
nephropathy [76]. The mean urinary volume and protein excretion in these rats are greater 
than healthy rats; also, the kidney weight increases in this strain, as the immunoreactivity of 
endothelial nitric oxide in the renal cortex of these rats is much higher [77].
3.3. Obesity
3.3.1. Obesity induced by diet
3.3.1.1. High-fat diet-fed rat
The increase in weight induced by a high-energy diet causes certain defects in the neuro-
nal response to negative feedback signals from circulating adiposity, such as insulin. Insulin 
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resistance of peripheral tissue involves cellular inflammatory responses that are caused by 
excess lipids. This model consists of rats fed with a HFD, mainly provoking DIO that has 
become one of the most important tools to understand the interactions of diets high in satu-
rated fat and the development of obesity [78].
3.3.1.2. Cafeteria diet-induced obese rat
In the above model, body weight increases dramatically and remains significantly elevated in 
CAF-fed rats. Also, hyperinsulinemia, hyperphagia, hyperglycemia and glucose intolerance 
are exaggeratedly elevated in CAF-fed rats compared with other models with HFD [79–81]. 
These models present increased adiposity and hepatosteatosis, brown fat and more inflam-
mation in the adipose tissue and liver. A CAF-fed rat model provides a model of human meta-
bolic syndrome with an exaggerated obesity phenotype with glucose intolerance [81]. With 
this model, it is possible to study the biochemical, genomic and physiological mechanisms of 
obesity and disease states related to metabolic diseases [79].
4. Conclusions
Animal research has been and continues to be essential for understanding the underlying 
mechanisms of most human and veterinary diseases. Metabolic diseases are complex and 
present heterogeneous clinical forms with significant impact in understanding metabolic 
disorders. The use of animal genetic models, mainly rodents (mouse and rat), has showed 
several advantages. However, it is necessary to consider the standards of care of laboratory 
animals, which are consistent and demand the necessary experimental conditions.
Author details
María José Hernández-Granados1, Joel Ramírez-Emiliano2 and Elena Franco-Robles1*
*Address all correspondence to: e.francorobles@ugto.mx
1 Department of Veterinary, University of Guanajuato, Mexico
2 Department of Medical Sciences, University of Guanajuato, Mexico
References
[1] Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabetic Medicine. 2005; 
22:359-370. DOI: 10.1111/j.1464-5491.2005.01499.x
[2] Song HK, Hwang DY. Use of C57BL/6N mice on the variety of immunological researches. 
Laboratory Animal Reserch. 2017;33(2):119-123. DOI: 10.5625/lar.2017.33.2.119
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy114
[3] Lee D, Park J, Kay K, Chrlstakls N, Oltval Z, Barabásl A. The implications of human 
metabolic network topology for disease comorbidity. Proccedings of the National Aca-
demy of Sciences of the United States of America. 2008;105:9880-9885. DOI: 10.1073/
pnas.0802208105
[4] Lera TA, Osburn AE. Genetic, endocrine & metabolic disorders. In: Osburn AE, edi-
tor. Oklahoma Notes (Clinical Sciences Review for Medical Licensure Developed at the 
University of Oklahoma College of Medicine). New York: NY; 1993. pp. 37-38. DOI: 
10.1007/978-1-4684-0450-0_4
[5] Taquchi A, Maruyama H, Nameta M, Yamamoto T, Marsuda J, Kulkarni AB, Yoshioka H, 
Ishii S. A symptomatic Fabry disease mouse model generated by inducing globotriosylce-
ramide synthesis. The Biochmical Journal. 2013;456(3):373-383. DOI: 10.1042/BJ20130825
[6] Shedlovsky A, McDonald JD, Symula D, Dove WF. Mouse models of human phenylke-
tonuria. Genetics. 1993;134(4):1205-12010. PMCID: PMC1205587
[7] Resnick JL, Nicholls RD, Wevrick R. Prader-Willi syndrome animal models working 
group. Mammalian Genome. 2013;24(5-6):165-178. Published online 2013 Apr 23. DOI: 
10.1007/s00335-013-9454-2
[8] Tang M, Siddiqi A, Witt B, et al. Subfertility and growth restriction in a new galactose-1 
phosphate uridylyltransferase (GALT)-deficient mouse model. European Journal of 
Human Genetics. 2014;22(10):1172-1179. DOI: 10.1038/ejhg.2014.12
[9] Jeyakumar M, Smith D, Eliott-Smith E, Cortina-Borja M, Reinkensmeier G, Butters T, 
Lemm T, Sandhoff K, Perry V, Dwek R, et al. An inducible mouse model of late onset Tay-
Sachs disease. Neurobiology of Disease. 2002;10(3):201-210. DOI: 10.1006/nbdi.2002.0511
[10] Ged C, Mendez M, Robert E, Lalanne M, Lamrissi-Garcia I, Costet P, Daniel JY, Dubus 
P, Mazurier F, Moreau-Gaudry F, de Verneuil H. A knock-in mouse model of congenital 
erythropoietic porphyria. Genomics. 2006;87(1):84-92, ISSN 0888-7543. DOI: 10.1016/j.
ygeno.2005.08.018
[11] Raben N, Nagaraju K, Lee A, Lu L, Rivera Y, Jatkar T, Hopwood J, Plotz P. Induction of 
tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient 
knockout mice. Transgenic Research. 2003;12(2):171-178. DOI: 10.1023/A:1022998010833
[12] Perl D, Schuchman E. Acid sphingomyelinase deficient mice: A model of types a and B 
Niemann-pick disease. Nature Genetics. 1995;10:288-293. DOI: 10.1038/ng0795-288
[13] Strauch O, Stypmann J, Reincheckel T, Peters C. Cardiac and ocular pathologies in a 
mouse model of mucopolysaccharidosis type VI. Pediatric Reearch. 2003;54(4):701-708. 
DOI: 10.1203/01.PDR.0000084085.65972.3F
[14] Cadone M, Polito VA, Pepe S, Mann L, D’Azzo A, Auricchio A, Ballabio A, Cosma MP. 
Correction of hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene 
delivery. Human Molecular Genetics. 2006;15(7):1225-1236. DOI: 10.1093/hmg/ddl038
Rodent Models of Obesity and Diabetes
http://dx.doi.org/10.5772/intechopen.74595
115
[15] Jinnah HA, Gage FH, Friedmann T. Animal models of Lesch-Nyhan syndrome. Brain 
Research Bulletin. 1990;25(3):467-475. PMID: 2292045
[16] Wang D, Shukla C, Liu X, et al. Characterization of an MPS I-H knock-in mouse that car-
ries a nonsense mutation analogous to the human IDUA-W402X mutation. Molecular 
Genetics and Metabolism. 2010;99(1):62-71. DOI: 10.1016/j.ymgme.2009.08.002
[17] Maclean KN, Sikora J, Kozich V, Jiang H, Greiner LS, Kraus E, Krijt J, Overdier KH, 
Collarf R, Brodksy GL, Meltesen L, Crnic LS. A novel transgenic mouse model of CBS-
deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hyper-
coagulative phenotype that is ameliorated by betaine treatment. Molecular Genetics and 
Metabolism. 2010;101(2-3):153-162. DOI: 10.1016/j.ymgme.2010.06.010
[18] Symula DJ, Shedlovsky A, Guillery EN, Dove WF. A candidate mouse model for Hartnup 
disorder deficient in neutral amino acid transport. Mammalian Genome. 1997;8(2):102-107. 
PMID: 9060408
[19] Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolc syndrome. 
Disease Models & Mechanisms. 2010;3:156-166. DOI: 10.1242/dmm.003467
[20] Hofmann S, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JA, Tschöp MH, 
Hui DY. Defective lipid delivery modulates glucose tolerance and metabolic response to 
diet in apolipoprotein E–deficient mice. American Diabetes Association. 2008;57(1):5-12. 
DOI: 10.2337/db07-0403
[21] Xu L, Shi L. Establishment of hyperuricemia rat model with different doses of hypoxan-
thine and oxonic acid potassium salt. Chinese Journal of Pharmacology and Toxicology. 
2008;22:306-310. DOI: 10.3867/j.issn.1000-3002.2008.04.011
[22] Inzucchi S, Sherwin R. The prevention of type 2 diabetes mellitus. Endocrinology and 
Metabolism Clinics of Nort America. 2005;34:199-219. DOI: 10.1016/j.ecl.2004.11.008
[23] Tsuboi R, Rifkin D. Recombinant basic fibroblast growth factor stimulates wound healing in 
healing-impaired db/db mice. The Journal of Experimental Medicine. 1990;172(1):245-251. 
DOI: 10.1084/jem.172.1.245
[24] Chen H, Charlat O, Tartaglia L, Woolf E, Weng X, Elli S, Lakey N, Culpepper J, More K, 
Breitbart R, Duyk G, Tepper R, Morgenstern J. Evidence that the diabetes gene encodes 
the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. 
Cell. 1996;84:491-495. DOI: 10.1016/S0092-8674(00)81294-5
[25] Lelter E, Strobel M, O’Nelll A, Schultz D, Schile A, Relfsnyder P. Comparison of two new 
mouse models of polygenic type 2 diabetes at the Jackson Laboratory, NONcNZO10Lt/J 
and TALLYHO/JngJ. Journal of Diabetes Research. 2013;2013:1-7. DOI: 10.1155/2013/165327
[26] Mao H, Roussos E, Péterfy M. Analysis of the diabetes-prone C57BLKS/J mouse strain 
reveals genetic contribution from multiple strain. Biochimica et Biophysica Acta. 2006; 
1762(4):440-446. DOI: 10.1016/j.bbadis.2006.01.002
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy116
[27] Naggert J, Mu L, Frankel W, Bailey D, Paigen B. Genomic analysis of the C57BL/Ks 
mouse strain. Mammalian Genome. 1995;6:131-133. PMID: 7766997
[28] Li Y, Han L, Xu M, Guo J, Feng M, Wang X. The primary research on the gut micro-
bes in KKAy mice. Indian Journal Microbiology. 2013;54(1):12-19. DOI: 10.1007/s12088- 
013-0410-3
[29] Iwatsuka H, Shino A. Studies in diabetogenic action of obesity in mice: Congenital insu-
lin resistance of KK mice. Endocrinologia Japonica. 1970;17(6):535-540. DOI: 10.1507/
endocrj1954.17.535
[30] Flowers J, Oler A, Nadler S, Chol Y, Schueler K, Yandell B, Kendziorski C, Attle A. 
Abdominal obesity in BTBR male mice is associated with peripheral but not hepatic 
insuin resistance. American Journal of Physiology Endocrinology and Metabolism. 2007; 
292(3):936-945. DOI: 10.1152/ajpendo.00370.2006
[31] Hudkins K, Pichaiwong W, Wietecha T, Kowalewska J, Banas M, Spencer M, Mühlfeld A, 
Koelling M, Pippin J, Shankland S, Askari B, Rabaglia M, Keller M, Attie A, Alpers C. 
BTRR Ob/Ob mutant mice progressive diabeti nephropathy. Journal of the American 
Society of Nephrology. 2010;21(9):1533-1542. DOI: 10.1681/ASN.2009121290
[32] Soler M, Riera M, Batlle D. New experimental models of diabetic nepropathy in mice 
models of type 2 diabetes: Efforts to replicate human nephropathy. Experimental Dia-
betes Research. 2012;2012:1-9. DOI: 10.1155/2012/616313
[33] Mohan S, Reddick R, Musi N, Hom D, Yan B, Prihoda T, Natarajan M, Abboud-Werner 
L. Diabetic Enos knockout mice develop distinct macro- and microvascular complica-
tions. Laboratory Investigation. 2008;88:515-528. DOI: 10.1038/labinvest.2008.23
[34] Zhao H, Wang S, Cheng H, Zhang M, Takahashi T, Fogo A, Breyer M, Harris R. 
Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in dia-
betic mice. Journal of the American Society of Nephrology. 2006;17:2664-2669. DOI: 
10.1681/ASN.2006070798
[35] Mathews C, Graser R, Savinov A, Serreze D, Leiter E. Unusual resistance of ALRyLt 
mouse β cells to autoimmune destruction: Role for β cell expressed resistance determi-
nants. PNAS. 2001;98(1):235-240. DOI: 10.1073/pnas.98.1.235
[36] Rohilla A, Ali S. Alloxan induced diabetes: Mechanisms and effects. International 
Journal of Research in Pharmacentical and Biomedical Sciences. 2012;3(2):819-823. ISSN: 
2229-3701
[37] Naggert J, Fricker L, Varlamov O, Nishina P, Rouille Y, Steiner D, Carroll R, Palgen B, 
Leiter E. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypepti-
dase E mutation which reduces enzyme activity. Nature Genetics. 1995;10:135-142. DOI: 
10.1038/ng0695-135
[38] Zhu X, Wu K, Rife L, Cawley N, Brown B, Adams T, Teofilo K, Lillo C, Williams D, 
Loh P, Craft C. Carboxypeptidase E is required for normal synaptic transmission from 
Rodent Models of Obesity and Diabetes
http://dx.doi.org/10.5772/intechopen.74595
117
photoreceptors to the inner retina. Journal of Neurochemistry. 2005;95:1351-1362. DOI: 
10.1111/j.1471-4159.2005.03460.x
[39] Hrbek T, Alves de Brito R, Wang B, Pletscher L, Cheverud J. Genetic characteriza-
tion of a new set of recombinant inbred lines (LGXSM) formed from the intercross of 
SM/J and LG/J inbred mouse strains. Mammalian Genome. 2006;17:417. DOI: 10.1007/
s00335-005-0038-7
[40] Cheverud J, Pletscher L, Vaughn T, Marshall B. Differential response to dietary fat in large 
(LG/J) and small (SM/J) inbred mouse strains. Physiological Genomics. 1999;15(1):33-39. 
PMID 11015559
[41] Leiter E, Prochazka M, Coleman D. The non-obese diabetic (NOD) mouse. American 
Journal of Pathology. 1987;128(2):380-383. PMCID: PMC1899627
[42] Lee C, Chen J, Naggert JK, Reifsnyder P, Wasserfall C, Arkinson M, Leiter EH. Novel leptin 
receptor mutation in NOD/LtJ mice suppresses tipe 1 diabetes progression: I. Patho-
physiological analysis. Diabetes. 2005;54(9):2525-2532. DOI: 10.2337/diabetes.54.9.2525
[43] Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, Kim JH, Sumner AD, Vary TC, Gardner 
TW, Bronson SK, Kim JK. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabe-
tes phenotypes including insulin resistance and cardiac remodeling. American Journal 
of Physiology Endocrinology and Metabolism. 2007;293(6):1687-1696. DOI: 10.1152/
ajpendo.00256.2007
[44] Pearson T, Shultz L, Lief J, Burzenski L, Goot B, Chase T, Foreman O, Rossini A, Bottino R, 
Trucco M, Greiner D. A new immunodeficient hyperglycaemic mouse model base don 
the Ins2Akita mutation for analyses of human islet and beta stem and progenitor cell func-
tion. Diabetologia. 2008;51(8):1449-1456. DOI: 10.1007/s00125-008-1057-1
[45] Barber A, Antonetti DA, Kern TS, Reiter CE, Soans RS, Krady JK, Levison SW, Gardner 
TW, Bronson SK. The Ins2Akita mouse as a modelo f early retinal complications in dia-
betes. Investigative Ophthalmology & Visual Science. 2005;46:2210-2218. DOI: 10.1167/
iovs.04-1340
[46] Deeds M, Anderson J, Armstrong A, Gastineau D, Hiddinga H, Jahangir A, Eberhardt N, 
Kudva Y. Single dose streptozotocin induced diabetes: Considerations for study design 
in islet transplantation models. Laboratory Animals. 2011;45(3):131-140. DOI: 10.1258/
la.2010.010090
[47] Lutz T, Woods S. Overview of animal models of obesity. Current Protocols in Phar-
macology. 2012;58(5.61):5.61.1-5.61.18. DOI: 10.1002/0471141755.ph0561s58
[48] Pelleymounter M, Cullen MJ, Baker M, Hecht R, Winters D, Boone T, Collins F. Effects 
of the obese gene production body weight regulation in Ob/Ob mice. Science. 1995; 
265(5223):540-543. PMID: 7624776
[49] Coleman D. Obese and diabetes: Two mutant genes causing diabetes-obesity syndromes 
in mice. Diabetologia. 1978;14:141-148. PMID: 350680
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy118
[50] Friedman J. Leptin, leptin receptors, and the control of body weight. Nutrition Reviews. 
1998;56:38-46. PMID: 9564176
[51] Nishikawa S, Yasoshima A, Doi K, Nakayama H, Uetsuka K. Involvement of sex, 
strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. 
Experimentals Animals. 2007;56(4):263-272. DOI: 10.1538/expanim.56263
[52] Wang C-Y, Liao J. A mouse model of diet-induced obesity and insulin resistance. 
Methods in Molecular Biology. 2012;821:421-433. DOI: 10.1007/978-1-61779-430-8_27
[53] Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, Zhang Z, Jung DY, Ola 
MS, Lanoue KF, Leiter EH, Kim JK. Hyperglucemia, maturity-onset obesity, and insulin 
resistance in NONcNZO10/LtJ males, a new mouse model if type 2 diabetes. American 
Journal Physiology, Endocrinology and Metabolism. 2007;293(1):327-336. DOI: 10.1152/
ajpendo.00376.2006
[54] Hirata T, Yoshitomi T, Inoue M, Iigo Y, Matsumoto K, Kubota K, Shinagawa A. Pathological 
and gene expression analysis of a polygenic diabetes model, NONcNZO10/LtJ mice. 
Gene. 2017;629:52-58. DOI: 10.1016/j.gene.2017.07.075
[55] Kim JH, Stewart TP, Soltani-Bejnood M, Wang L, Fortuna JM, Mostafa OA, Moustaid-
Moussa N, Shoieb AM, McEntee MF, Wang Y, Bechtel L, Naggert JK. Phenotypic 
characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. The Journal of 
Endocrinology. 2006;191(2):437-446. DOI: 10.1677/joe.1.06647
[56] Rhee SD, Sung YY, Lee YS, Kim JY, Jung WH, Kim MJ, Lee MS, Lee MK, Yang SD, 
Cheon HG. Obesity of TallyHO/JngJ mouse is due to increased food intake with early 
development of leptin resistance. Experimental and Clinical Endocrinology & Diabetic. 
2011;119(4):243-251. DOI: 10.1055/s-0030-1267202
[57] Kim JH, Stewart TP, Zhang W, Kim H, Nishana P, Naggert J. Type 2 diabetes mouse 
model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obe-
sity. Physiological Genomics. 2005;22:171-181. DOI: 10.1152/physiolgenomics.00197.2004
[58] Coleman D, Eicher E. Fat (fat) and tubby (tub): Two autosomal recessive mutations caus-
ing obesity syndromes in the mouse. The Journal of Heredity. 1990;81(6):424-427. DOI: 
10.1093/oxfordjournals.jhered.a111019
[59] Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, Berkemeier LR, Misumi DJ, 
Holmgren L, Charlat O, Woolf EA, Tayber O, Brody T, Shu P, Hawkins F, Kennedy B, 
Baldini L, Ebeling C, Alperin GD, Deeds J, Lakey ND, Culpepper J, Chen H, Glücksmann-
Kuis MA, Carlson GA, Duyk GM, Moore KJ. Identification and characterization of the 
mouse obesity gene tubby: A member of a nove gene family. Cell. 1996;85(2):281-290. 
DOI: 10.1016/S0092-8674(00)81104-6
[60] Bryzgalova G, Lundholm L, Portwood N, Gustafsoon JA, Khan A, Efecdic S, Dahlman-
Wright K. Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen 
in high-fat diet-fed mice. American Journal Physiology Endocrinology and Metabolism. 
2008;295:904-912. DOI: 10.1152/ajpendo.90248.2008
Rodent Models of Obesity and Diabetes
http://dx.doi.org/10.5772/intechopen.74595
119
[61] Lin S, Thomas TC, Storlien LH, Huang XF. Development of high fat diet-induced obesity 
and leptin resistance in C57Bl=6J mice. International Journal of Obesity. 2000;24:639-646. 
DOI: 1 0.1038/sj.ijo.0801209
[62] Ferreira AV, Mario EG, Porto LC, Andrade SP, Bolton LM. High-carbohydrate diet 
selectively induce tumor necrosis factor-α production in mice liver. Inflammation. 
2011;34(2):139-145. DOI: 10.1007/s10753-010-9217-0
[63] Chaumontet C, Azzout-Marniche D, Blais A, Chalvon-Dermersay T, Nadkani N, Piedcoq 
J, Fromentin G, Tomé D, Even P. Rats prone to obesity under a high-carbohydrate diet 
have increased post-meal CCK mRNA expression and characteristics of rats fed a high-
glycemic index diet. Frontiers in Nutrition. 2015;2(22):1-10. DOI: 10.3389/fnut.2015.00022
[64] Thomas CD, Peters JC, Reed GW, Abumrad NN, Sun M, Hill JO. Nutrient balance and 
energy expenditure during ad libitum feeding of high-fat and high-carbohydrate diets in 
humans. The American Journal of Clinical Nutrition. 1992;55(5):934-942. PMID: 1570800
[65] Wong S, Chin K, Suhaimi F, Fairus A, Ima-Nirwana S. Animal models of metabolic syn-
drome: A review. Nutrition & Metabolism. 2016;13:65. DOI: 10.1186/s12986-016-0123-9
[66] Ishibashi S, Brown M, Goldstein J, Gerard R, Hammer R, Herz J. Hypercholesterolemia 
in low density lipoprotein receptor knockout mice and its reversal by adenovirus-
mediated gene delivery. The Journal of Clinical Investigation. 1993;92(2):883-893. DOI: 
10.1172/JCI116663
[67] Diani AR, Sawada GA, Hannah BA, Jodelis KS, Connell MA, Connell CL, Vidmar TJ, 
Wyse BM. Analysis of pancreatic islet cells and hormone content in the spontaneously 
diabetic KKAy mouse by morphometry, immunocytochemistry and radioimmunoas-
say. Virchowa Archiv. A, Pathological Anatomy and Histopathology. 1987;412(1):53-61. 
DOI: 10.1007/BF00750731
[68] Collins S, Martín T, Surwit R, Robidoux J. Genetic vulnerability to diet-induced obe-
sity in the C57BL/6J mouse: Physiological and molecular characteristics. Physiology & 
Behavior. 2004;81:243-248. DOI: 10.1016/j.physbeh.2004.02.006
[69] Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, Surwit RS. Fat, carbohydrate, and 
calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism. 
2004;53(4):454-457. DOI: 10.1016/j.metabol.2003.11.018
[70] Sena CM, Barosa C, Nunes E, Seica R, Jones JG. Sources of enfogenous glucose produc-
tion in the Goto-Kakizaki diabetic rat. Diabetes & Metabolism. 2007;33(4):296-302. DOI: 
10.1016/j.diabet.2007.03.002
[71] Akash MS, Rehman K, Chen S. Goto-Kakizaki rats: Its suitbility as non-obese diabetic 
animal model for spontaneous type 2 diabetes mellitus. Current Diabetes Reviews. 
2013;9(5):1-10. DOI: 10.2174/15733998113099990069
[72] Tourreal C, Bailbé D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exen-
din-4 stimulate b-cell neogenesis in streptozotocin-treated newborn rats resulting in 
persistently improved glucose homeostasis at adult age. Diabetes. 2001;50:1562-1570. 
PMID: 11423477
Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy120
[73] Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet.fed 
and low-dose streptozotocin-trated rat: A model fot type 2 diabetes and pharmacological 
screening. Pharmacological Research. 2005;52:313-320. DOI: 10.1016/j.phrs.2005.05.004
[74] Jonas JC, Sharmas A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner-Weir S, 
Weir G. Chronic hyperglycemia triggers loss of pancreatic b cell differentiation in an ani-
mal model of diabetes. The Journal of Biological Chemistry. 1999;274(20):14112-14121. 
PMID: 10318828
[75] Finegood D, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat 
pancreas: Estimation with a simple mathematical model. Diabetes. 1995;44(3):259-256. 
DOI: 10.2337/diab.44.3.249
[76] Tesch G, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nep-
hrology. 2007;12(3):261-266. DOI: 10.1111/j.1440-1797.2007.00796.x
[77] Nakhoul F, Abassi Z, Morgan M, Sussan S, Mirsky N. Inhibition of diabetic nephropa-
thy in rats by an oral antidiabetic material extracted fron yeast. Jounal of the American 
Society of Nephrorology. 2006;17:127-131. DOI: 10.1681/ASN.2005121333
[78] Posey K, Clegg D, Printz R, Byun J, Morton G, Vivekanandan-Giri A, Pennathur S, 
Baskin D, Heineche J, Woods S, Schwartz M, Niswender D. Hypothalamic proinglam-
matory lipid accumulation, inflammation and insuline resistance in rats fed a high-fat 
diet. American Journal of Endocrinology and Metabolism. 2009;296:1003-1012. DOI: 
10.1152/ajpendo.90377.2008
[79] Sampey B, Vanhoose A, Winfield H, Freemerman A, Muehlbauer M, Fueger P, Newgard 
C, Makowski L. Caferetia diet is a robust model of human metabolic syndrome with 
liver and adipose inflammation: Comparison to high-fat diet. Obesity. 2011;19:1109-
1117. DOI: 10.1038/oby.2011.18
[80] Johnson A, Wilkerson M, Sampey B, Troester M, Hayes N, Makowski L. Cafeteria diet-
induced obesity causes oxidative damage in white adipose. Biochemical and Biophysical 
Research Communications. 2016;473(2):545-550. DOI: 10.1016/j.bbrc.2016.03.113
[81] Rothwell N, Stock MA. Role for insulin in the diet-induce thermogenesis of cafeteria-fed 
rats. Metabolism. 1981;30:673-678. DOI: 10.1016/0026-0495(81)90
Rodent Models of Obesity and Diabetes
http://dx.doi.org/10.5772/intechopen.74595
121

